Ryan Stempfle - CareRx VP Division
| CHHHF Stock | USD 1.40 0.00 0.00% |
Insider
Ryan Stempfle is VP Division of CareRx
| Phone | 416 927 8400 |
| Web | https://www.carerx.ca |
CareRx Management Efficiency
The company has return on total asset (ROA) of 0.0204 % which means that it generated a profit of $0.0204 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4946) %, meaning that it generated substantial loss on money invested by shareholders. CareRx's management efficiency ratios could be used to measure how well CareRx manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jose Simas | Elanco Animal Health | 53 | |
| Thomas Larssen | Aurora Cannabis | N/A | |
| Ryan Hellard | SNDL Inc | 36 | |
| R Hoover | Elanco Animal Health | 75 | |
| Janet Vergis | Teva Pharma Industries | 57 | |
| Abbas Hussain | Teva Pharma Industries | 55 | |
| Shawn McKee | Elanco Animal Health | N/A | |
| Rajeev Modi | Elanco Animal Health | 43 | |
| Ellen Brabander | Elanco Animal Health | 62 | |
| Andrew Stordeur | SNDL Inc | 44 | |
| Ronit SatchiFainaro | Teva Pharma Industries | 48 | |
| Joyce Lee | Elanco Animal Health | 47 | |
| Scott Ferguson | Elanco Animal Health | 46 | |
| Eric Drape | Teva Pharma Industries | 62 | |
| Kare Schultz | Teva Pharma Industries | 63 | |
| Racquel Mason | Elanco Animal Health | 50 | |
| Rick Savone | Aurora Cannabis | N/A | |
| Eli Shani | Teva Pharma Industries | N/A | |
| Marcela Kirberger | Elanco Animal Health | 57 | |
| Galia Inbar | Teva Pharma Industries | N/A | |
| Paul Herendeen | Elanco Animal Health | 65 | |
Management Performance
| Return On Equity | -0.49 | |||
| Return On Asset | 0.0204 |
CareRx Leadership Team
Elected by the shareholders, the CareRx's board of directors comprises two types of representatives: CareRx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CareRx. The board's role is to monitor CareRx's management team and ensure that shareholders' interests are well served. CareRx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CareRx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Puneet Khanna, Chief Officer | ||
| Ryan Stempfle, VP Division | ||
| Adrianne Campeau, Chief Officer | ||
| David Murphy, CEO Pres | ||
| Andrew Mok, Chief Officer | ||
| Paul Rakowski, Gen Devel |
CareRx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is CareRx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.49 | |||
| Return On Asset | 0.0204 | |||
| Profit Margin | (0.09) % | |||
| Operating Margin | 0.02 % | |||
| Current Valuation | 170.84 M | |||
| Shares Outstanding | 51.96 M | |||
| Shares Owned By Insiders | 30.25 % | |||
| Shares Owned By Institutions | 32.82 % | |||
| Price To Earning | 13.57 X | |||
| Price To Book | 1.78 X |
Currently Active Assets on Macroaxis
Other Information on Investing in CareRx Pink Sheet
CareRx financial ratios help investors to determine whether CareRx Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CareRx with respect to the benefits of owning CareRx security.